This article is more than 5 years old. Information may no longer be current.
Latanoprost patent upheld in New Jersey
Click Here to Manage Email Alerts
Pfizer has prevailed in a patent infringement suit in which Par Pharmaceutical was seeking approval to market a generic version of latanoprost, according to separate press releases issued by the two companies.
Pfizer noted that Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey held Pharmacia’s patent on formulations and uses was valid, infringed and enforceable against Par. The court further issued an injunction against Par’s drug application until Pharmacia’s patent expires in 2011.
One of the patents in dispute was deemed not to have been infringed, according to both companies. The court declared the ’368 patent unenforceable due to inequitable conduct on the part of Pharmacia to submit pertinent patent information.
Latanoprost is marketed by Pfizer as Xalatan.